CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

被引：0
|
作者：
Xinna Zhou
Guoliang Qiao
Xiaoli Wang
Qingkun Song
Michael A. Morse
Amy Hobeika
William R. Gwin
Jun Ren
H. Kim Lyerly
机构：
[1] Capital Medical University Cancer Center,Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines
[2] Beijing Shijitan Hospital,Department of Medical Oncology
[3] Capital Medical University,Department of Medicine
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Surgery
[5] Beijing Cancer Hospital and Institute,Department of Medicine
[6] Peking University School of Oncology,undefined
[7] Duke University Medical Center,undefined
[8] Duke University Medical Center,undefined
[9] University of Washington,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
CYP1A1; Single nucleotide polymorphism; Breast cancer; Liver metastasis; Docetaxel; Thiotepa; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 372
页数：7
相关论文
共 50 条
  • [31] Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.
    Chan, S
    Romieu, G
    Huober, J
    Delozier, T
    Tubiana-Hulin, M
    Lluch, A
    Schneeweiss, A
    Llombart, A
    Carrasco, E
    Fumoleau, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 24S - 24S
  • [32] A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines
    Campone, Mario
    Dobrovolskaya, Natalya
    Tjulandin, Serjei
    Chen, Shin-Chen
    Fourie, Sameul
    Mefti, Fawzia
    Konstantinova, Maria
    Lefresne, Florence
    Meheust, Nadege
    Jassem, Jacek
    BREAST JOURNAL, 2013, 19 (03): : 240 - 249
  • [33] Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients.
    Yu, Jing
    Dong, Ningning
    Yan, Ying
    Shao, Bin
    Di, Lijun
    Song, Guohong
    Che, Li
    Jia, Jun
    Jiang, Hanfang
    Liang, Xu
    Zhu, Yulin
    Wang, Chaoying
    Zahng, Jie
    Zhu, Budong
    Zhou, Xinna
    Wang, Xiaoli
    Yang, Huabing
    Ren, Jun
    Lyerly, Herbert Kim
    CANCER RESEARCH, 2013, 73 (08)
  • [34] Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
    Vamvakas, L.
    Karampeazis, A.
    Ardavanis, A.
    Souglakos, I.
    Kalbakis, K.
    Vardakis, N.
    Kouroussis, Ch.
    Malamos, N.
    Varthalitis, I.
    Mavroudis, D.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S49 - S49
  • [35] Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: A phase 1 study
    Brugnatelli, S
    Danova, M
    De Bella, MT
    Vaglica, M
    Manuguerra, G
    Riccardi, A
    Palmeri, S
    ONCOLOGY, 2002, 62 (01) : 33 - 38
  • [36] Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer
    Wildiers, H.
    Neven, P.
    Christiaens, M. R.
    Squifflet, P.
    Amant, F.
    Weltens, C.
    Smeets, A.
    van Limbergen, E.
    Debrock, G.
    Renard, V.
    Van Eenoo, L.
    Wynendaele, W.
    Paridaens, R.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 588 - 594
  • [37] Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study
    Rosati, G.
    Bilancia, D.
    Germano, D.
    Dinota, A.
    Romano, R.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 128 - 132
  • [38] An interim safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine plus pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin plus pegfilgrastim (DE) in the neoadjuvant treatment of operable breast cancer.
    Steger, G. G.
    Greil, R.
    Samonigg, H.
    Jakesz, R.
    Bartsch, R.
    Mlineritsch, B.
    Melbinger-Zeinitzer, E.
    Marth, C.
    Schippinger, W.
    Gnant, M. F.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S156 - S156
  • [39] Final Results of a Three-Arm Randomised Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines.
    Campone, M.
    Dobrovolskaya, N.
    Tjulandin, S.
    Chen, S-C
    Fourie, S.
    Mefti, F.
    Konstantinova, M.
    Lefresne, F.
    Meheust, N.
    Jassem, J.
    CANCER RESEARCH, 2011, 71
  • [40] Use of MDR1/ABCB1 single nucleotide polymorphism (SNP) as a prognostic factor for breast cancer patients receiving docetaxel plus doxorubicin neoadjuvant chemotherapy
    Kim, H. J.
    Keam, B.
    Im, S.
    Ham, H. S.
    Oh, D.
    Kim, J.
    Han, W. S.
    Kim, T.
    Park, I. A.
    Bang, Y. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345